Natalie J. Miller

Natalie J. Miller

Auto-generated profile, based on publicly available information

Natalie J. Miller

Department of Medicine, Divisions of Dermatology and Medical Oncology, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2013 in Current Treatment Options in Oncology
Verified
Journal Article
Closed access
PDF file
NMNatalie J. Miller
Natalie J. Miller
SBShailender Bhatia
Shailender Bhatia
UPUpendra Parvathaneni
Upendra Parvathaneni
JIJayasri G. Iyer
Jayasri G. Iyer
PNPeter P. Nghiem
Peter P. Nghiem

27 November 2018 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
NMNatalie J. Miller
Natalie J. Miller
CCCandice D. Church
Candice D. Church
SFSteven P. Fling
Steven P. Fling
RKRima Kulikauskas
Rima Kulikauskas
NRNirasha Ramchurren
Nirasha Ramchurren
PNPeter P. Nghiem
Peter P. Nghiem
Background Merkel cell carcinoma (MCC) is an aggressive skin cancer that frequently responds to anti-PD-1 therapy. MCC is associated with sun exposure and, in 80% of cases, Merkel cell polyomavirus (MCPyV). MCPyV-specific T and B cell responses provide a unique opportunity to study cancer-specific immunity throughout PD-1 blockade therapy. Methods Immune responses were assessed in patients (n = 26) with advanced MCC receiving pembrolizumab. Peripheral blood mononuclear cells (PBMC) were collected at baseline and throughout treatment. MCPyV-oncoprotein antibodies were quantified and T cells were assessed for MCPyV-specificity via tetramer staining and/or cytokine secretion. Pre-treatment tumor biopsies were analyzed for T cell receptor clonality. Results MCPyV oncoprotein antibodies were detectable in 15 of 17 (88%) of virus-positive MCC (VP-MCC) patients. Antibodies decreased in 10 of 11 (91%) patients with responding tumors. Virus-specific T cells decreased over time in patients who had a complete response, and increased in patients who had persistent disease. Tumors that were MCPyV(+) had a strikingly more clonal (less diverse) intratumoral TCR repertoire than virus-negative tumors (p = 0.0001). Conclusions Cancer-specific T and B cell responses generally track with disease burden during PD-1 blockade, in proportion to presence of antigen. Intratumoral TCR clonality was significantly greater in VP-MCC than VN-MCC tumors, suggesting expansion of a limited number of dominant clones in response to fewer immunogenic MCPyV antigens. In contrast, VN-MCC tumors had lower clonality, suggesting a diverse T cell response to numerous neoantigens. These findings reveal differences in tumor-specific immunity for VP-MCC and VN-MCC, both of which often respond to anti-PD-1 therapy.